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and 26 Gy (>G2 neutropenia) and 24 Gy, 27 Gy and 30 Gy 
(>G3 leukopenia). On the whole cohort, within a dose range 
between 25 and 40 Gy, this probability rises from 30.3% to 
69.1% for >G2 neutropenia and from 17.5% to 57.1% for >G3 
leukopenia. For node positive patients these ranges were 
16.5%-93.7% (>G2 neutropenia) and 6.7%-77.6% (>G3 
leukopenia). 
 
Conclusion: LKB modeling seems to suggest that LSBM mean 
dose should be kept below 32 Gy to minimize > G2-G3 HT in 
anal cancer patients treated with IMRT and concurrent 
chemotherapy. The sensitivity of LSBM and its contribution to 
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Purpose or Objective: RTCT is widely used as treatment in 
LARC before surgery. A challenging aspect for tailoring 
radiation dose prescription is prediction of cases that will 
show a pathological complete response (PCR) after surgery, 
because they have better expectation in survival outcomes. 
“Radiomics” refers to the extraction and analysis of large 
amounts of advanced quantitative imaging features with high 
throughput from medical images. Up today radiomics findings 
in LARC have been limited either to small case series and CT 
or PET scan imaging. Objective of this study is to find a 
radiomics signature able to distinguish PCR patients using 
pre-treatment MR. 
Material and Methods: Histologically proven LARC patients 
were recruited retrospectively since May 2008 to December 
2014. They were staged by T2 MR, high resolution ( .7 x .7 x 3 
mm pixel spacing on x-y-z axes) perpendicular to tumor 
major axis oblique scans, before RTCT start. Finally they 
underwent to surgery with definition of pathological 
response. All patients were addressed to RTCT treatment 
with 50.4 Gy @ 1.8 Gy/fr prescription dose on 
GTV+surrounding mesorectum (PTV1) and 45 Gy @ 1.8 Gy/fr 
on lymphatic drainage (PTV2). For radiomics analysis GTV was 
delineated on pre treatment MRI by a radiologist and a 
radiation oncologist experienced in GI. Images were 
processed by using a home-made software. Before analysis 
MR images were pre-processed using a normalization 
procedure and application of Laplacian of Gaussian (LoG) 
filter on raw data. After pre-processing, GTV volumes were 
analyzed extracting 1st order features (Kurtosis, Skewness 
and Entropy). These features were extracted by scanning all 
possible values of σ in LoG filter from 0.3 to 6 (step 0.01). A 
total number of 570 x 3 features were analyzed respect to 
the PCR in order to detect the most significant ones using 
AUC and Mann-Whitney test. Tumor clinical (cT, cN) and 
geometrical features (volume, surface, volume/surface ratio) 
were finally added for building a multivariate logistic model 
and predicting PCR. Model performance was evaluated by 
ROC analysis and internal bootstrapping for detecting 
calibration error (TRIPOD Ib classification). 
 
Results: 173 patients have been enrolled in this study. 1st 
order features analysis shows as candidate-to-analysis ones 
the Skewness (σ=0.69 - SK069) and Entropy (σ=0.49 - EN049). 
Multivariate logistic model shows as significant covariates cT 
(p-val = 0.003), SK069 (p-val = 0.006) and EN049 (p-val = 
0.049). AUC of model is 0.73 and bootstrap based internal 
calibration shows prediction mean absolute error = 0.017. 
The model has been summarized in a nomogram. 
 
 
Conclusion: This is the first radiomics model able to predict 
PCR in LARC patients only using pre-treatment imaging. 
Model performance is fair but its limitation is in the 
availability of internal validation alone. External validation is 
already planned. Use of such a model could address patients 
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Purpose or Objective: Predictive and prognostic models in 
locally advanced rectal cancer have been developed in the 
last years. Starting with predictions models on pathologic 
complete response (as intermediate endpoint), afterwards 
local recurrence (LR), distant metastasis (DM) and overall 
survival (OS) at different time points (e.g. 5 or 10 years post-
treatment) finally resulting in a model for the aggregate 
outcome, disease free survival (DFS). The current work aimed 
to reproduce the prediction models for LR, DM and OS, and to 
investigate the time dependence of these models. 
 
Material and Methods: The dataset characteristics are shown 
in Table 1. This pooled dataset merged the datasets of the 
ACCORD, TME, CAO/ARO/AIO '94, Polish, FFCD, Italian 
(Sainato) and UK (Glynne-Jones) trials. As the current pooled 
dataset contains different trials, we used 20% of patients 
(stratified on the trial) as a validation dataset. In accordance 
to the methods used in previous work, we trained prediction 
models for the outcomes LR, DM and OS on this larger 
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dataset. Prediction model variables were selected by 
evaluating the univariate Kaplan Meier curves for every 
variable at a significance level of p<0.05. Afterwards, a Cox 
proportional hazards model and logistic regression models (in 
the latter situation a model for every month) were trained. 
Furthermore, we analyzed the covariate weights for the 
regression models. Finally, all the models were validated on 
discriminative ability using the Area under the Receiver 




Results: The AUC values for the prediction models are shown 
in figure 1 (blue: previous model, red: current Cox PH model, 
black: current logistic regression models). In general, the 
discriminative performance of the logistic regression model is 
higher in comparison to the newly trained Cox proportional 
hazards model or the original models, for all three outcomes. 
The covariates which changed the most over time were 
adjuvant chemo (LR, DM & OS), neo-adjuvant chemo (LR & 




Conclusion: Based on the current results, analyzed on the 
current dataset, we have shown that the logistic regression 
model (separate model for every time point) may perform 
better than models trying to cover the complete follow-up 
period. This may be due to the optimization capabilities, 
when training a new model for every follow-up time point, 
but might be susceptible for overfitting. From a clinical 
perspective, this could be plausible as the influence of 
variables (e.g. (neo-)adjuvant chemotherapy) may vary 
during the follow-up period and targeted outcome and could 
show how clinical and/or treatment decisions have influence 
on the patient outcome over time. Future work also involves 
handling of missing values, which is a major concern when 
merging trial datasets. 
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Purpose or Objective: To investigate long term outcome and 
predictors between two schedules of platin based 
preoperative radiochemotherapy (RTCT) 
 
Material and Methods: Patients with rectal adenoca, MRI 
based stage cT3N0-N2, were randomized into two arms: 
1) PLAFUR: RT= 50.4 Gy; Concurrent chemotherapy (CT)= 
CDDP 60 mg m2 (days 1-29) + 5FU continuous infusion in 96 h 
(days 1-4 and 29-32) 
2) TOMOX-RT: RT=50.4 Gy; CT= Tomudex 3 mg / m2 + 
oxaliplatin 130 mg / m2 (days 1, 19 and 38). 
Restaging at 6-8 weeks after the end of RTCT, followed by 
surgery in 1-2 weeks. 
Adjuvant CT was recommended in ypN1-2. 
Local control (LC), metastases-free survival (MFS), disease-
free survival (DFS) and overall survival (OS) were analyzed. 
Predictive endpoints of clinical outcome were tested by 
univariate and multivariate analysis. The investigated 
variables were: (i) patients (age, sex), (ii) therapy (RTCT 
schedule, adjuvant CT, surgery type, colostomy), (iii) tumor 
related (cT, cN, ypT, ycN, TRG grade, site of primary T). 
 
Results: From 2002 to 2005, 164 patients were enrolled (M: F 
= 104: 60); 83 were randomized to PLAFUR and 81 to TOMOX-
RT. The median follow-up was 120.2 months (5.8-152.5).  
The 10-years rates of the efficacy endpoints, per arm, were 
as follows: LC: PLAFUR= 89.2% , TOMOX-RT= 96.3% 
(p=0.0757); MFS: PLAFUR= 81.9% , TOMOX-RT= 81.5% 
(p=0.987) ; DFS: PLAFUR= 78.3% , TOMOX-RT= 77.8% 
(p=0.982); OS: PLAFUR =50%, TOMOX-RT= 50% (p=0.918) 
TOMOX-RT showed a non-significantly higher rate of ypT0 
compared to PLAFUR: 35.8% vs 24.1% (p = 0.102), 
respectively. 
Sphincter-saving surgery procedure was applied in: PLAFUR= 
87.9%, TOMOX-RT= 86.4%. 
Grade 3-4 acute toxicity occurred in: 7.1% in the PLAFUR arm 
vs 16.4% in the TOMOX-RT arm.  
Confirmed predictors of outcome were found: 
- For LC: at univariate analisys= ypT; ypN, TRG Grade; at 
multivariate analysis= TRG Grade (p = 0.0126) 
- For MFS: at univariate analisys= age ypT, ypN and TRG 
Grade; at multivariate analysis= TRG Grade (p = 0.0255) 
- For DFS: at univariate analisys= age ypT, ypN and TRG 
Grade; at multivariate analysis= TRG Grade (p = 0.0224) 
- For OS: at univariate analisys= age ypT, ypN and TRG Grade; 
at multivariate analysis= no predictor was significantly 
associated. 
 
Conclusion: The TOMOX-RT schedule allowed higher non-
significant local control, and comparable clinical outcome to 
the compared schedule. Moreover the ypT downstaging was 
significantly improved. Acute toxicity was comparable 
between arms. 
The TRG Grade was a good independent variable predicting 
LC, MFS and DFS, but not OS.  
 
 
